NCT02526550View on ClinicalTrials.gov

Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Encephalitis
Interventions
BIOLOGICAL

Live attenuated chimeric Japanese Encephalitis vaccine

0.5 mL dose containing ≥ 4.0 log10 plaque forming units (PFU) administered via the subcutaneous route into the left thigh

BIOLOGICAL

Inactivated Hepatitis A vaccine

0.5 mL liquid dose for intramuscular injection administered via the intramuscular route into the right thigh

All Listed Sponsors
collaborator

Sanofi Pasteur, a Sanofi Company

INDUSTRY

lead

Siriraj Hospital

OTHER

NCT02526550 - Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX | Biotech Hunter | Biotech Hunter